Replies to post #226421 on Biotech Values

[biocqr]

ACHN > now trading @ 6.28 so the CVRs are basically free...

The transaction includes the potential for additional consideration in the form of non-tradeable contingent value rights (CVRs), which will be paid to Achillion shareholders if certain clinical and regulatory milestones are achieved within specified periods. These include $1.00 per share for the U.S. FDA approval of danicopan and $1.00 per share for ACH-5228 Phase 3 initiation.

[biocqr]

What are the odds this becomes becomes a target of an FTC antitrust investigation?